Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug 31:15:5061-5068.
doi: 10.2147/IDR.S379502. eCollection 2022.

Biofilm-Associated Multi-Drug Resistance in Hospital-Acquired Infections: A Review

Affiliations
Review

Biofilm-Associated Multi-Drug Resistance in Hospital-Acquired Infections: A Review

Muluneh Assefa et al. Infect Drug Resist. .

Abstract

Biofilm-related multi-drug resistance (MDR) is a major problem in hospital-acquired infections (HAIs) that increase patient morbidity and mortality rates and economic burdens such as high healthcare costs and prolonged hospital stay. This review focuses on the burden of bacterial biofilm in the hospital settings, their impact on the emergence of MDR in the HAIs, biofilm detection methods, recent approaches against biofilms, and future perspectives. The prevalence of biofilm-associated MDR among HAIs ranges from 17.9% to 100.0% worldwide. The predominant bacterial isolates causing HAIs in recently published studies were S. aureus, A. baumannii, K. pneumoniae, and P. aeruginosa. In addition to the use of qualitative and quantitative methods to detect biofilm formation, advanced PCR-based techniques have been performed for detecting biofilm-associated genes. Although there are suggested therapeutic strategies against biofilms, further confirmation of their efficacy for in vivo application and antibiotics targeting biofilm-associated genes/proteins to minimize treatment failure is required for the future.

Keywords: biofilm; hospital-acquired infections; multi-drug resistance.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
The link between biofilm-hospital-infection.

References

    1. Hurlow J, Couch K, Laforet K, Bolton L, Metcalf D, Bowler P. Clinical biofilms: a challenging frontier in wound care. Adv Wound Care. 2015;4(5):295–301. doi:10.1089/wound.2014.0567 - DOI - PMC - PubMed
    1. Jamal M, Ahmad W, Andleeb S, et al. Bacterial biofilm and associated infections. J Chin Med Assoc. 2018;81(1):7–11. doi:10.1016/j.jcma.2017.07.012 - DOI - PubMed
    1. Santos A, Galdino ACM, Mello T, et al. What are the advantages of living in a community? A microbial biofilm perspective! Mem Inst Oswaldo Cruz. 2018;113. doi:10.1590/0074-02760180212 - DOI - PMC - PubMed
    1. Preda VG, Săndulescu O. Communication is the key: biofilms, quorum sensing, formation and prevention. Discoveries. 2019;7(3):e10. doi:10.15190/d.2019.13 - DOI - PMC - PubMed
    1. Elhabibi T, Ramzy S. Biofilm production by multi drug resistant bacterial pathogens isolated from patients in intensive care units in Egyptian hospitals. J Microb Biochem Technol. 2017;9(4):151–158.

LinkOut - more resources